prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37  |review
In order to introduce affordable CD4 tests into practice, 6 issues need to be considered: 1/ Advantages of volumetric ‘single-platform’ cytometers in terms of running costs, 2/ Introduction of primary CD4 gating 4 with the use of a single CD4 reagent (instead of 6-9 reagents as currently used expensively), 3/ The availability of monoclonal CD4 antibodies 4 conjugated to fluorochromes detectable with inexpensive red diode lasers, 4/ Fixatives for short term use, e. g., TransFix from NEQAS, UK, 5/ Standard cells 1 fixed for long periods to facilitate participation in international quality control and 6/ A search for simple volumetric flow cytometers that handle well in tropical conditions. See Janossy, Jani & Goehde Br J Haemat 111, 2000.

Enumeration of CD4 T lymphocytes is the most sensitive indicator for assessment. This indicator, together with the estimation of plasma viral load constitutes 2 universally accepted monitoring tools aside from antibody tests, reverse transcriptase (RT-PCR) and the Western blot test separating viral proteins in gel. Tests based on the polymerase chain reaction (PCR) are usually for DNA and here the reaction is reversed just as retro- means reversed. EIA was given in the anterior Diagnosis. EIA deserves more development as a cheap method for CD4+ counting.